SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conferenc ...

Core Viewpoint - PROCEPT BioRobotics Corporation has successfully completed three prostate cancer procedures using Aquablation therapy in an Ambulatory Surgery Center, marking a significant milestone in the treatment of localized prostate cancer [1][3]. Group 1: Aquablation Therapy and Clinical Trial - Aquablation therapy is an image-guided, minimally invasive surgical procedure that utilizes a robotically-controlled waterjet to remove diagnosed cancer and most of the prostate [2]. - The WATER IV PCa Trial is a U.S. FDA investigational device exemption (IDE) approved clinical study comparing Aquablation therapy with radical prostatectomy for men with localized prostate cancer [2]. - The trial aims to evaluate the safety and efficacy of Aquablation therapy for men with Grade Group 1 to 3 localized prostate cancer [2]. Group 2: Treatment Setting and Outcomes - Dr. Rahul Mehan has chosen to conduct the randomized Aquablation therapy trial at an Ambulatory Surgery Center, demonstrating that early-stage prostate cancer can be safely treated in this setting [3]. - All procedures were completed successfully, with patients discharged the same day without complications, indicating a safe prostate resection [3]. - The approach of using Aquablation therapy could lead to a more scalable and cost-effective care model in the evolving healthcare market [3]. Group 3: Industry Impact and Future Prospects - The unique design of the WATER IV PCa trial focuses on harm reduction and could potentially change the treatment paradigm for localized prostate cancer among millions of men [3]. - The FDA's approval of the IDE for this trial reflects a thorough review process and opens up possibilities for this novel treatment approach [3]. - PROCEPT BioRobotics is committed to advancing patient care through transformative urology solutions, with a significant body of clinical evidence supporting the benefits of Aquablation therapy [5].

Core Insights - PROCEPT BioRobotics Corporation announced that Aquablation therapy has been assigned a Category I CPT code effective January 1, 2026, marking a significant milestone for the company and the urology community [1][3] - The new Category I CPT code 52XX1 will replace the previous Category III CPT code 0421T and is associated with a proposed national average payment of approximately $540 under the 2026 Medicare Physician Fee Schedule [2][3] - The transition to a Category I code is expected to enhance surgeon adoption and increase patient access to Aquablation therapy, which offers durable symptom relief with a low risk of sexual side effects [3] Payment Structure - The 2026 proposed payment for Aquablation therapy is set at 16.14 total RVUs, compared to 15.82 total RVUs for TURP, which translates to an average payment of approximately $529 [3] - The Proposed Physician Fee Schedule was released on July 14, 2025, and will undergo a public comment period until September 2025, with a final rule expected in November 2025 [4] Aquablation Therapy Overview - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for benign prostatic hyperplasia (BPH), providing personalized treatment planning based on real-time imaging [5][6] - The technology allows for precise removal of prostate tissue while preserving critical anatomy related to erectile and ejaculatory function, making it suitable for a wide range of patients [5][6] - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for Aquablation therapy [6]

Group 1 - The company, PROCEPT BioRobotics, is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at four investor conferences in May and June 2025, including the Bank of America Health Care Conference and the Jefferies Global Healthcare Conference [1][2] - PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] Group 2 - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), impacting approximately 40 million men in the U.S. [3] - The company has developed a significant body of clinical evidence, with over 150 peer-reviewed publications supporting the benefits of Aquablation therapy [3] - The company aims to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions [3]